$750M Namenda Deal OK'd But 21% Atty Fee Request In Doubt
A Manhattan federal judge on Wednesday approved a landmark $750 million settlement over allegations that an Allergan PLC subsidiary thwarted generic competition for its Alzheimer's drug Namenda, but cast doubt on...To view the full article, register now.
Already a subscriber? Click here to view full article